In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global biopharmaceutical company, have announced positive topline results from the Phase 2 ...

Ltd. (Ono) has made the strategic business decision to allow its option to acquire Equillium’s rights to itolizumab to expire. The decision was not related to data from any clinical program and ...

– Key Data Readouts from Sentinel Participant Expected in 2Q 2025 and 3Q 2025 – NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company ...